Table 3.
Association between the cell adhesion molecule 1/human epidermal growth factor receptor 2/signal transducer and activator of transcription 3 axis and clinico-pathological factors.
| CADM1 n (%) | HER2 n (%) | STAT3 n (%) | ||||||||
| Clinical features | n (total) | Negative | Positive | P-value | Negative | Positive | P-value | Negative | Positive | P-value |
| Age (yr) | .45 | .12 | .18 | |||||||
| ≤ 50 | 93 | 41 (44.09) | 52 (55.91) | 81 (87.1) | 12 (12.9) | 46 (49.46) | 47 (50.54) | |||
| > 50 | 87 | 44 (50.57) | 43 (49.43) | 68 (78.16) | 19 (21.84) | 34 (39.08) | 53 (60.92) | |||
| Histological grade | < .0001 | .002 | < .0001 | |||||||
| Benign | 20 | 0 (0) | 20 (100) | 20 (100) | 0 (0) | 18 (90) | 2 (10) | |||
| Borderline | 30 | 5 (16.67) | 25 (83.33) | 28 (93.33) | 2 (6.67) | 22 (73.33) | 8 (26.67) | |||
| Low | 50 | 22 (44) | 28 (56) | 44 (88) | 6 (12) | 34 (48) | 26 (52) | |||
| High | 80 | 58 (72.5) | 22 (27.5) | 57 (71.25) | 23 (28.75) | 16 (20) | 64 (80) | |||
| FIGO Stage | .005 | .02 | < .0001 | |||||||
| I/II | 47 | 21 (44.68) | 26 (55.32) | 42 (89.36) | 5 (10.64) | 26 (55.32) | 21 (44.68) | |||
| III/IV | 83 | 59 (71.08) | 24 (28.92) | 59 (71.08) | 24 (28.92) | 14 (16.87) | 69 (83.13) | |||
| Lymph node metastasis | .004 | .009 | < .0001 | |||||||
| No | 78 | 40 (51.28) | 38 (48.72) | 67 (85.90) | 11 (14.10) | 34 (43.59) | 44 (56.41) | |||
| Yes | 52 | 40 (76.92) | 12 (23.08) | 34 (65.38) | 18 (34.62) | 6 (11.54) | 46 (88.46) | |||
Data are presented as n (%). Comparisons were performed using the Chi-squared test. P < .05 was considered statistically significant.
CADM1 = cell adhesion molecule 1, FIGO, International Federation of Gynecology and Obstetrics, HER2 = human epidermal growth factor receptor 2, HGSC = high-grade serous ovarian carcinoma, LGSC = low-grade serous ovarian carcinoma, SBT = serous borderline tumor, STAT3 = signal transducer and activator of transcription.